177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03805594 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma
Stage IV Prostate Cancer
Stage IVA Prostate Cancer
Stage IVB Prostate Cancer

Interventions

DRUG: Lutetium Lu 177-PSMA-617
BIOLOGICAL: Pembrolizumab

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]